Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ: KNSA · Real-Time Price · USD
79.40
+0.93 (1.19%)
Aug 21, 2026, 12:31 PM EDT - Market open
KNSA Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 840.85 | 677.56 | 423.24 | 270.26 | 220.18 | 38.54 | |
Revenue Growth | 58.85% | 60.09% | 56.61% | 22.75% | 471.24% | - |
Cost of Revenue | 382.55 | 307.22 | 189.22 | 89.93 | 46.97 | 9.94 |
Gross Profit | 458.3 | 370.35 | 234.02 | 180.33 | 173.21 | 28.61 |
Selling, General & Admin | 230.9 | 196.27 | 168.01 | 129.43 | 97.95 | 85.95 |
Research & Development | 127.15 | 96.85 | 111.62 | 76.1 | 65.49 | 99.3 |
Operating Expenses | 358.05 | 293.13 | 279.63 | 205.52 | 163.44 | 185.25 |
Operating Income | 100.25 | 77.22 | -45.62 | -25.2 | 9.77 | -156.64 |
Other Non Operating Income (Expenses) | 14 | 11.65 | 9.46 | 8.54 | 1.25 | 0.1 |
Pretax Income | 114.25 | 88.87 | -36.15 | -16.65 | 11.03 | -156.54 |
Income Tax Expense | 33.59 | 29.86 | 7.04 | -30.74 | -172.34 | 1.39 |
Net Income | 80.66 | 59.01 | -43.19 | 14.08 | 183.36 | -157.92 |
Net Income to Common | 80.66 | 59.01 | -43.19 | 14.08 | 183.36 | -157.92 |
Net Income Growth | 1583.88% | - | - | -92.32% | - | - |
Shares Outstanding (Basic) | 76 | 74 | 71 | 70 | 69 | 69 |
Shares Outstanding (Diluted) | 82 | 79 | 71 | 72 | 70 | 69 |
Shares Change | 9.97% | 10.58% | -0.69% | 2.13% | 2.69% | 10.89% |
EPS (Basic) | 1.06 | 0.80 | -0.60 | 0.20 | 2.64 | -2.30 |
EPS (Diluted) | 0.99 | 0.75 | -0.60 | 0.20 | 2.60 | -2.30 |
EPS Growth | 1399.63% | - | - | -92.31% | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 182.84 | 136.42 | 25.41 | 13.17 | 5.7 | -126.71 |
Free Cash Flow Per Share | 2.23 | 1.73 | 0.36 | 0.18 | 0.08 | -1.85 |
Gross Margin | 54.50% | 54.66% | 55.29% | 66.72% | 78.67% | 74.22% |
Operating Margin | 11.92% | 11.40% | -10.78% | -9.32% | 4.44% | -406.38% |
Profit Margin | 9.59% | 8.71% | -10.21% | 5.21% | 83.28% | -409.72% |
Free Cash Flow Margin | 21.74% | 20.13% | 6.00% | 4.87% | 2.59% | -328.75% |
EBITDA | 102.04 | 78.78 | -43.92 | -22.86 | 12.18 | -154.28 |
EBITDA Margin | 12.13% | 11.63% | -10.38% | -8.46% | 5.53% | - |
D&A For EBITDA | 1.79 | 1.55 | 1.7 | 2.34 | 2.4 | 2.36 |
EBIT | 100.25 | 77.22 | -45.62 | -25.2 | 9.77 | -156.64 |
EBIT Margin | 11.92% | 11.40% | -10.78% | -9.32% | 4.44% | - |
Effective Tax Rate | 29.40% | 33.60% | - | - | - | - |
Revenue as Reported | 840.85 | 677.56 | 423.24 | 270.26 | 220.18 | 38.54 |
Advertising Expenses | - | 12.06 | 11.43 | 9.07 | 5.73 | - |